Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives

Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives

ABSTRACT Triple‐negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer, characterized by poor prognosis and limited therapeutic options. Although neoadjuvant chemotherapy (NACT) remains the established treatment approach, its suboptimal efficacy associated with TNBC highlight...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhenjun Huang, Qing Peng, Luhui Mao, Wenhao Ouyang, Yunjing Xiong, Yujie Tan, Haizhu Chen, Zebang Zhang, Tang Li, Yuanjia Hu, Ying Wang, Wei Zhang, Herui Yao, Yunfang Yu
Format:	Article
Language:	English
Published:	Wiley 2025-03-01
Series:	MedComm – Future Medicine
Subjects:	future perspectives immunotherapy neoadjuvant chemotherapy platinum‐based agents targeted therapy triple‐negative breast cancer
Online Access:	https://doi.org/10.1002/mef2.70013
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
by: Yichao Du, et al.
Published: (2025-08-01)

Does T1c–2N0–1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
by: Ruiliang Chen, et al.
Published: (2024-12-01)

Comparison of neoadjuvant and adjuvant chemotherapy for operable triple-negative breast cancer before the era of immune checkpoint inhibitors: A retrospective study from the Japanese National Clinical Database-Breast Cancer Registry
by: Tomoe Taji, et al.
Published: (2025-06-01)

Effect of HER2-low expression on the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer
by: Lin-Yu Xia, et al.
Published: (2025-06-01)

Comprehensive genomic profiling can predict response to neoadjuvant chemotherapy in triple-negative breast cancer
by: Monika Drobniene, et al.
Published: (2025-04-01)

Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
by: Sarah Talamantes, et al.
Published: (2020-10-01)

SCNN1A expression in triple-negative breast cancer: clinical implications for prognosis and neoadjuvant therapy response
by: Xin Jin, et al.
Published: (2025-04-01)

The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer
by: Chikako Funasaka, et al.
Published: (2025-01-01)

Nomogram for the prediction of the prognosis of patients with triple-negative invasive ductal carcinoma of breast after neoadjuvant chemotherapy
by: Qiuyu Yang, et al.
Published: (2025-07-01)

An ultrasound-based model for predicting the response to neoadjuvant chemotherapy in early stage triple negative breast cancer patients
by: Yuyang Tong, et al.
Published: (2025-07-01)

The role of platinum-based antineoplastic drugs and their impact on complete pathological response and prognosis in patients with BRCA-associated triple-negative breast cancer after neoadjuvant treatment: a single institution experience
by: D. A. Enaldieva, et al.
Published: (2023-06-01)

The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis
by: Eva L. Claassens, et al.
Published: (2025-04-01)

Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer
by: O. O. Gordeeva, et al.
Published: (2020-11-01)

Oral microbiome components predict response to neoadjuvant chemotherapy in triple-negative breast cancer patients
by: Xiaoyan Fu, et al.
Published: (2025-07-01)

The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients
by: N. N. Babyshkina, et al.
Published: (2020-04-01)

Central nervous system relapse in triple-negative breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy: A retrospective cohort analysis
by: Gabriel Berlingieri Polho, et al.
Published: (2025-10-01)

Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)
by: Jieun Lee, et al.
Published: (2025-08-01)

Prognostic and Predictive Markers for Early Stage Triple‐Negative Breast Cancer Treated With Platinum‐Based Neoadjuvant Chemotherapy
by: Zhenhui Zhao, et al.
Published: (2024-10-01)

Correlations of phosphorylated Nrf2 with responses to neoadjuvant chemotherapy in patients with triple-negative breast cancer
by: Jiaxuan Yu, et al.
Published: (2025-07-01)

Intratumoral microbiota-aided fusion radiomics model for predicting tumor response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer
by: Yilin Chen, et al.
Published: (2025-03-01)

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017-12-01)

Impact of Neoadjuvant Therapy on PD-L1 Expression in Triple-Negative Breast Cancer and Correlation with Clinicopathological Factors
by: Nevena Ilieva, et al.
Published: (2024-11-01)

The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis
by: Sedat Yıldırım, et al.
Published: (2025-05-01)

Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer
by: Jaimin R. Shah, et al.
Published: (2025-05-01)

Development and Validation of a New Immune-Inflammatory-Nutritional Score to Predict Pathological Complete Response in Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy: A Two-Center Study
by: Wang S, et al.
Published: (2025-07-01)

Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world study
by: Youzhao Ma, et al.
Published: (2025-06-01)

Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer—an open-label phase 2 randomized controlled trial
by: Vinod K. Ramani, et al.
Published: (2025-06-01)

Correction: Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer—an open-label phase 2 randomized controlled trial
by: Vinod K. Ramani, et al.
Published: (2025-08-01)

The impact of circWWC3 on neoadjuvant therapy for triple-negative breast cancer and the construction of a nomogram for predicting pathological complete response after neoadjuvant therapy
by: Haoqi Wang, et al.
Published: (2025-07-01)

Pathological complete response of locally advanced triple-negative breast cancer: case report
by: V. V. Konstantinova, et al.
Published: (2024-09-01)

Establishment and clinical application of a prognostic index for inflammatory status in triple-negative breast cancer patients undergoing neoadjuvant therapy using machine learning
by: Hao Sun, et al.
Published: (2024-12-01)

The overview of modern approaches in treatment of triple negative breast cancer
by: A. A. Kharitonova, et al.
Published: (2020-03-01)

Current status and prospects of tertiary lymphoid structure heterogeneity in predicting response to neoadjuvant therapy and characterizing immune microenvironment in triple-negative breast cancer
by: WANG Qing, YU Yushuai, WANG Chenxi, JIANG Zirong, LI Jialu, TANG Shicong, SONG Chuangui
Published: (2025-02-01)

Use of medications in women with triple-negative breast cancer between 2018 and 2019 in a Brazilian public hospital: a retrospective study
by: Monique Cristine da Silva Pires, et al.
Published: (2025-02-01)

The role of neoadjuvant chemotherapy of triple-negative breast cancer in St. Petersburg City Clinical Oncological Dispensary
by: A. G. Manikhas, et al.
Published: (2016-09-01)

Case Report: Hepatic sarcoidosis-like reaction from neoadjuvant pembrolizumab in early-stage triple-negative breast cancer
by: Yujing Tan, et al.
Published: (2025-06-01)

Results of combination treatment for triple-negative breast cancer
by: M. A. Sekundova, et al.
Published: (2014-07-01)

The efficacy and immune-mediated safety of PD-1/PD-L1 combined with neoadjuvant chemotherapy in triple-negative breast cancer: a meta-analysis
by: Xiao Yan, et al.
Published: (2025-08-01)

Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer
by: Maximilian Marhold, et al.
Published: (2023-12-01)

Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancer
by: Yuhan Wei, et al.
Published: (2025-01-01)